Carbamazepine extended-release capsules: a new treatment option for bipolar I disorder.
Journal Article (Journal Article;Review)
Carbamazepine has a long history in psychiatry and neurology. More recently, carbamazepine extended-release capsules have been approved by the US Food and Drug Administration for the treatment of manic and mixed episodes associated with bipolar I disorder. This decision represents a significant step forward for the agent, which was first described to have efficacy in the disorder in the early 1970s. Approval of carbamazepine extended-release capsules was aided by two large placebo-controlled, 3-week trials. Using nearly identical protocols, these trials demonstrated that monotherapy with carbamazepine extended-release capsules was effective for the treatment of acute mania in patients with bipolar I disorder. Recent data collected based on this new formulation of carbamazepine illustrate the need for education about the utility of this compound in bipolar disorder.
Full Text
Duke Authors
Cited Authors
- Weisler, RH
Published Date
- September 2005
Published In
Volume / Issue
- 5 / 5
Start / End Page
- 587 - 595
PubMed ID
- 16162082
Pubmed Central ID
- 16162082
Electronic International Standard Serial Number (EISSN)
- 1744-8360
Digital Object Identifier (DOI)
- 10.1586/14737175.5.5.587
Language
- eng
Conference Location
- England